医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Research and Markets: Epidemiology: Inflammatory Bowel Disease – Early diagnosis and improved survival lead to increased patient populations

2012年09月26日 AM02:17
このエントリーをはてなブックマークに追加


 

DUBLIN

Research and Markets (http://www.researchandmarkets.com/research/kmdx39/epidemiology) has announced the addition of the “Epidemiology: Inflammatory Bowel Disease – Early diagnosis and improved survival lead to increased patient populations” report to their offering.

Inflammatory bowel diseases (IBDs) are mainly composed of three chronic diseases; Crohn’s disease, ulcerative colitis, and indeterminate colitis. Although the etiology of inflammatory bowel disease is largely unknown, the incidence of IBD has substantially increased in the past decade.

Gain insight into market potential, including a robust 10-year epidemiology forecast of Crohn’s disease and ulcerative colitis prevalent cases.Gain insights into the current and future prevalent trends of Crohn’s disease and ulcerative colitis in the next 10 years.Understand the key epidemiologic risk factors associated with inflammatory bowel diseases.Since the 1950s, the overall incidence of IBD has gradually increased, although the increase in the incidence of ulcerative colitis (UC) precedes the increase in Crohn’s disease (CD) by approximately 15-20 years.

Across the seven major markets, Datamonitor estimates that in 2011 there were approximately 913,000 and 1.7 million prevalent cases of Crohn’s disease and ulcerative colitis, respectively.Between 2011 and 2021, Datamonitor estimates that prevalent cases of both Crohn’s disease and ulcerative colitis will increase.How will the IBD patient population change over the next decade in the seven major markets?What are the estimated prevalent cases of Crohn’s disease and ulcerative colitis in the seven major markets?

Key Topics Covered:

– OVERVIEW

– EXECUTIVE SUMMARY

– DISEASE DEFINITION AND DIAGNOSIS CRITERIA

– GLOBAL VARIATION AND HISTORICAL TRENDS

– RISK FACTORS

– EPIDEMIOLOGIC FORECASTING OF INFLAMMATORY BOWEL DISEASE

– EPIDEMIOLOGIC RESULTS

– DISCUSSION

– BIBLIOGRAPHY

– TABLES

FIGURES

Companies Mentioned

– Bull

– Hutchison 3G UK Limited

– Metro AG

– Schindler Holding Ltd.

For more information visit http://www.researchandmarkets.com/research/kmdx39/epidemiology

CONTACT

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 欧州委員会、未治療のCD30陽性ステージ4ホジキンリンパ腫成人患者に対する数十年ぶりの新規治療法となるアドセトリス(ブレンツキシマブ・ベドチン)とAVDの併用を承認
  • Positive Phase 3 Study for Tezacaftor/Ivacaftor Combination in Children Aged 6-11 Years with Cystic Fibrosis Supports European Medicines Agency Submission
  • SpeeDx开发呼吸道病毒复合检测
  • 欧盟委员会核准ADCETRIS® (brentuximab vedotin)联合AVD用于既往未曾治疗的CD30+ IV期霍奇金淋巴瘤成人患者,这是数十年来首个新治疗方案
  • New Mallika Sherawat Billboards: ‘Go Vegan for Someone You Love’